Christopher Coleman

I'll verify the attorney's background and the tracked cases before writing.

Let me dig deeper to pin down the right attorney and the tracked cases.

Disambiguation note up front: "Christopher Coleman" is a common name in IP practice, and I could not confirm a single authoritative match. The firm field in the tracked data (Sterne, Kessler, Goldstein & Fox) points to a Washington, DC–based Sterne Kessler attorney identified in the U.S. News law firm directory as "Chris Coleman," DC-licensed and a 2023 JD graduate. Separately, there is a Christopher S. Coleman, an IP litigation partner at Perkins Coie in Phoenix, and a Christopher McKee at Banner & Witcoff (different surname) — neither should be conflated with this profile. The findings below are limited to what is verifiable, and I flag where the record is thin.

Specialty / focus areas. The observable practice is life sciences / pharmaceutical patent work, not standards or electronics work. Both tracked matters are captioned around Breckenridge Pharmaceutical, Inc., a generic-drug manufacturer, and the pro hac vice docket entry in Breckenridge Pharmaceutical, Inc. v. Hetero USA Inc., No. 1:24-cv-00571 (D. Del.) lists a Christopher Coleman alongside Sterne Kessler's Dennies Varughese and other attorneys for the Hetero/Camber defendants — an ANDA/Hatch-Waxman posture concerning U.S. Patent No. 11,013,729, which had a parallel PTAB proceeding (IPR2025-01107). No source supports any Wi-Fi, standards-essential, or mechanical practice for this attorney, so I have not attributed one.

Side preference. The tracked data shows 0 plaintiff-side and 2 defendant-side appearances (one as counsel, one as lead counsel), and the verifiable docket work is likewise defense-side representation of generic-drug manufacturers. On the current record this reads as a defense-oriented practice; there is no evidence of NPE/PAE-side assertion or of plaintiff-side prosecution-and-assertion work. Note the tension, however, that a 2023 JD graduate is an unusual candidate for a "lead counsel" designation — that entry may reflect a pro hac vice or co-counsel designation rather than substantive first-chair responsibility, and I could not verify it.

Firm context. The tracked firm is Sterne Kessler (Washington, DC), a firm with a nationally prominent PTAB/post-grant and life sciences practice. No prior-firm history or in-house affiliation is documented for this attorney in the sources reviewed.

Notable matters / PTAB. The tracked matters are Unified Patents, LLC v. Breckenridge Pharmaceutical Inc. (defendant side, Sterne Kessler, counsel) — Unified Patents is a defensive aggregator known for validity challenges, so this caption suggests a challenge to a Breckenridge-owned patent with Breckenridge on the defense side, though I could not confirm the forum or proceeding type — and one untitled matter in which he appears as lead counsel. Neither has a verifiable verdict, settlement, or Federal Circuit outcome tied to this attorney. Sterne Kessler filed the patent owner's preliminary response in IPR2025-01107 concerning Breckenridge's '729 patent, but I did not find Coleman personally named in that PTAB filing, so regular IPR/PGR appearance by him is unconfirmed rather than established.

Bar / education. Reported DC bar license; JD 2023 (law school not identified in the sources reviewed), per the U.S. News law firm directory listing — treat that profile match as probable but unconfirmed.